Incyte’s Jakafi disappoints in severe Covid-19
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Bergenbio dream lives on, despite Genmab's broken Axl
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
The pandemic response roars on
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
Five Prime looks to turn a corner
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
SITC 2020 – second chances for Merck & Co and Oncosec
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
